# Non-Invasive Urine-Based Diagnostic Technologies for Early Bladder Cancer

**Authors:** Zhe Hao, Shuhua Yue, Lin Yao, Yanqing Gong, Jian Yu, Liqun Zhou

PMC · DOI: 10.3390/bios16030171 · Biosensors · 2026-03-20

## TL;DR

This paper reviews non-invasive urine-based technologies for early bladder cancer detection, aiming to replace traditional invasive methods.

## Contribution

The paper introduces and evaluates five emerging non-invasive diagnostic approaches for bladder cancer using urine analysis.

## Key findings

- AI-augmented urine cytology and genomic biomarker assays show promise in improving diagnostic accuracy.
- DNA methylation profiling and RNA biomarkers offer potential for early-stage bladder cancer detection.
- Protein/peptide/metabolite detection methods like ELISA and mass spectrometry are being explored for non-invasive diagnosis.

## Abstract

Bladder cancer (BCa) is a major global urinary tract malignancy characterized by high incidence, frequent recurrence, and significant mortality. Early diagnosis is crucial for improving prognosis and minimizing invasive procedures; however, current standard techniques, cystoscopy and urine cytology, are limited by invasiveness, cost, low sensitivity, and subjectivity. This has spurred the development of non-invasive diagnostic strategies based on urine analysis. This review highlights five emerging approaches: AI-augmented urine cytology, genomic biomarker assays (e.g., PCR and NGS for mutations and copy-number variations), DNA methylation profiling, RNA biomarkers (mRNA, miRNA, lncRNA), and protein/peptide/metabolite detection utilizing ELISA, SERS, nanozymes, and mass spectrometry. We assess the diagnostic accuracy, innovations, and clinical potential of each, while addressing persisting issues such as lack of standardization, high costs, and insufficient sensitivity for early-stage lesions. Future directions include integrating multi-omics data with AI, advancing point-of-care devices, and conducting large-scale multicenter trials. Together, these developments promise to shift BCa management toward molecular-based early detection, enabling more precise, non-invasive, and personalized patient care.

## Linked entities

- **Diseases:** bladder cancer (MONDO:0004986)

## Full-text entities

- **Genes:** CFAP58 (cilia and flagella associated protein 58) [NCBI Gene 159686] {aka C10orf80, CCDC147, SPGF49, bA127L20.4, bA127L20.5, bA554P13.1}, TWIST1 (twist family bHLH transcription factor 1) [NCBI Gene 7291] {aka ACS3, BPES2, BPES3, CRS, CRS1, CSO}, DLX1 (distal-less homeobox 1) [NCBI Gene 1745], MAGEA3 (MAGE family member A3) [NCBI Gene 4102] {aka CT1.3, HIP8, HYPD, MAGE3}, CEACAM5 (CEA cell adhesion molecule 5) [NCBI Gene 1048] {aka CD66e, CEA}, MIR215 (microRNA 215) [NCBI Gene 406997] {aka MIRN215, miRNA215, mir-215}, MIR141 (microRNA 141) [NCBI Gene 406933] {aka MIRN141, mir-141}, BLNK (B cell linker) [NCBI Gene 29760] {aka AGM4, BASH, BLNK-S, LY57, SLP-65, SLP65}, NDRG2 (NDRG family member 2) [NCBI Gene 57447] {aka SYLD}, NUMA1 (nuclear mitotic apparatus protein 1) [NCBI Gene 4926] {aka NMP-22, NUMA}, MIR100HG (mir-100-let-7a-2-mir-125b-1 cluster host gene) [NCBI Gene 399959] {aka AGD1, linc-NeD125, lncRNA-N2}, NRN1 (neuritin 1) [NCBI Gene 51299] {aka NRN, dJ380B8.2}, RUNX3 (RUNX family transcription factor 3) [NCBI Gene 864] {aka AML2, CBFA3, PEBP2aC}, H19 (H19 imprinted maternally expressed transcript) [NCBI Gene 283120] {aka ASM, ASM1, BWS, D11S813E, GMRSP, LINC00008}, ZSCAN12 (zinc finger and SCAN domain containing 12) [NCBI Gene 9753] {aka ZFP96, ZNF29K1, ZNF305, ZNF96, dJ29K1.2}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, ASTN1 (astrotactin 1) [NCBI Gene 460] {aka ASTN}, EOMES (eomesodermin) [NCBI Gene 8320] {aka TBR2}, POU4F2 (POU class 4 homeobox 2) [NCBI Gene 5458] {aka BRN3.2, BRN3B, Brn-3b}, MIRLET7C (microRNA let-7c) [NCBI Gene 406885] {aka LET7C, MIRNLET7C, hsa-let-7c, let-7c}, FGFR3 (fibroblast growth factor receptor 3) [NCBI Gene 2261] {aka ACH, CD333, CEK2, HSFGFR3EX, JTK4}, FAM107A (family with sequence similarity 107 member A) [NCBI Gene 11170] {aka DRR1, TU3A}, IQGAP3 (IQ motif containing GTPase activating protein 3) [NCBI Gene 128239], CA9 (carbonic anhydrase 9) [NCBI Gene 768] {aka CAIX, MN}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, HOXA9 (homeobox A9) [NCBI Gene 3205] {aka ABD-B, HOX1, HOX1.7, HOX1G}, ETS2 (ETS proto-oncogene 2, transcription factor) [NCBI Gene 2114] {aka ETS2IT1}, MIR205 (microRNA 205) [NCBI Gene 406988] {aka MIRN205, mir-205}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, GP5 (glycoprotein V platelet) [NCBI Gene 2814] {aka CD42d, GPV}, PLAU (plasminogen activator, urokinase) [NCBI Gene 5328] {aka ATF, BDPLT5, QPD, UPA, URK, u-PA}, ANXA10 (annexin A10) [NCBI Gene 11199] {aka ANX14}, MIR143 (microRNA 143) [NCBI Gene 406935] {aka MIRN143, mir-143}, TERT (telomerase reverse transcriptase) [NCBI Gene 7015] {aka CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1}, PCDH17 (protocadherin 17) [NCBI Gene 27253] {aka PCDH68, PCH68}, ONECUT2 (one cut homeobox 2) [NCBI Gene 9480] {aka OC-2, OC2}, H4C6 (H4 clustered histone 6) [NCBI Gene 8361] {aka H4, H4/c, H4FC, HIST1H4F}, UCA1 (urothelial cancer associated 1) [NCBI Gene 652995] {aka CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36}, OTX1 (orthodenticle homeobox 1) [NCBI Gene 5013], GAS5 (growth arrest specific 5) [NCBI Gene 60674] {aka NCRNA00030, SNHG2}, IGF2 (insulin like growth factor 2) [NCBI Gene 3481] {aka C11orf43, GRDF, IGF-II, PP9974, SRS3}, BMP4 (bone morphogenetic protein 4) [NCBI Gene 652] {aka BMP2B, BMP2B1, MCOPS6, OFC11, ZYME}, ANG (angiogenin) [NCBI Gene 283] {aka ALS9, HEL168, RAA1, RNASE4, RNASE5}
- **Diseases:** amino acid metabolism disorder (MESH:D000592), carcinoma in situ (MESH:D002278), UTUC (MESH:D014571), prostate cancer (MESH:D011471), micro- (MESH:C536681), urethral injury (MESH:D014526), cancer (MESH:D009369), NMIBC (MESH:D000093284), hematuria (MESH:D006417), urinary tract infections (MESH:D014552), metabolic abnormalities (MESH:D008659), injury to (MESH:D014947), nasopharyngeal carcinoma (MESH:D000077274), infection (MESH:D007239), genitourinary system cancers (MESH:D014565), invasive (MESH:D009361), inflammatory (MESH:D007249), urothelial cancer (MESH:D014523), DL (MESH:C537113), renal cell carcinoma (MESH:D002292), urinary tract malignancy (MESH:D014570), schistosomiasis (MESH:D012552), BCa (MESH:D001749), hepatocellular carcinoma (MESH:D006528), cystitis (MESH:D003556)
- **Chemicals:** fatty acid (MESH:D005227), VOC (MESH:D055549), oil (MESH:D009821), pentanol (MESH:D000439), acetone (MESH:D000096), 2-pentanone (MESH:C076402), 3-methylbutanal (MESH:C032251), ethanolamine (MESH:D019856), sulfur compounds (MESH:D013457), nonanal (MESH:C008664), aldehydes (MESH:D000447), Fe3O4@SiO2 (-), decanal (MESH:C021170), 2-butanone (MESH:C005222), propanoate (MESH:D011422), silver (MESH:D012834), ketones (MESH:D007659), phenylacetate (MESH:C025136), biphenyl (MESH:C010574), deoxyribose (MESH:D003855), lipid (MESH:D008055), L-tyrosine (MESH:D014443), cisplatin (MESH:D002945), tryptophan (MESH:D014364), gold (MESH:D006046), hexanal (MESH:C010463), ketone bodies (MESH:D007657), 2-methoxyphenol (MESH:D006139), alcohols (MESH:D000438), tetradecane (MESH:C024713), adenosine (MESH:D000241), GO (MESH:C000628730), L-arginine (MESH:D001120), phenylacetaldehyde (MESH:C013192), isovaleric acid (MESH:C008216)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13024073/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13024073/full.md

## References

147 references — full list in the complete paper: https://tomesphere.com/paper/PMC13024073/full.md

---
Source: https://tomesphere.com/paper/PMC13024073